Sugi Predict

Sugi Predict / Targets / CDKN1A

CDKN1A

Cyclin-dependent kinase inhibitor 1 · P38936 · CDKN1A on Sugi Atlas →

2,279 patent compounds predicted against CDKN1A, 1,829 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2833833 SCHEMBL2833833 0.44 5/20
SCHEMBL377887 SCHEMBL377887 0.38 4/20
SCHEMBL2853032 SCHEMBL2853032 0.58 3/20
SCHEMBL2920423 SCHEMBL2920423 0.57 3/20
SCHEMBL2918432 SCHEMBL2918432 0.56 3/20
SCHEMBL2926345 SCHEMBL2926345 0.56 3/20
SCHEMBL2839683 SCHEMBL2839683 0.56 3/20
SCHEMBL2925650 SCHEMBL2925650 0.56 3/20
SCHEMBL2924396 SCHEMBL2924396 0.54 3/20
SCHEMBL2925167 SCHEMBL2925167 0.54 3/20
SCHEMBL2922685 SCHEMBL2922685 0.53 3/20
SCHEMBL4068166 SCHEMBL4068166 0.52 3/20
SCHEMBL2915153 SCHEMBL2915153 0.51 3/20
SCHEMBL1366540 SCHEMBL1366540 0.50 3/20
SCHEMBL2921214 SCHEMBL2921214 0.43 3/20
SCHEMBL2843704 SCHEMBL2843704 0.41 3/20
SCHEMBL147454 SCHEMBL147454 0.39 3/20
SCHEMBL147081 SCHEMBL147081 0.39 3/20
SCHEMBL378025 SCHEMBL378025 0.39 3/20
SCHEMBL913965 SCHEMBL913965 0.62 2/20

Clinical trials — most relevant to CDKN1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics PHASE1RECRUITING
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC PHASE1WITHDRAWN
Genetic Analysis of Familial Melanoma nanCOMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy nanCOMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDKN1A binder may also engage these)

ProteinNameSimilarity
P39689 — 1.000 P39689 →
O19002 — 1.000 O19002 →
P46529 — 0.984 P46529 →
A6QLA6 — 0.984 A6QLA6 →
Q60439 — 0.983 Q60439 →
Q8CFU8 — 0.982 Q8CFU8 →
Q0X0C4 — 0.982 Q0X0C4 →
B1H224 — 0.982 B1H224 →
P46414 — 0.981 P46414 →
Q8CHM3 — 0.981 Q8CHM3 →
O94992 — 0.981 O94992 →
O19001 — 0.980 O19001 →
P46527 — 0.980 P46527 →
Q8R409 — 0.980 Q8R409 →
Q8NCF5 — 0.979 Q8NCF5 →
Q58CQ0 — 0.979 Q58CQ0 →
Q6PAN7 — 0.979 Q6PAN7 →
MSL1 Male-specific lethal 1 homolog 0.979 landscape →
Q9Y6A5 — 0.979 Q9Y6A5 →
Q8BY98 — 0.979 Q8BY98 →
Q6PB51 — 0.978 Q6PB51 →
Q8IXH6 — 0.978 Q8IXH6 →
Q29RJ9 — 0.978 Q29RJ9 →
Q7TN12 — 0.978 Q7TN12 →
Q5EE38 — 0.978 Q5EE38 →
Q9Z0E3 — 0.978 Q9Z0E3 →
A2AEV7 — 0.978 A2AEV7 →
Q5SX79 — 0.978 Q5SX79 →
Q3KP66 — 0.978 Q3KP66 →
Q9GLZ9 — 0.977 Q9GLZ9 →